Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy

Min Deng\(^a\)\(^{b}\)\(^{c}\), Shaohua Li\(^a\)\(^{b}\)\(^{c}\), Qiaoxuan Wang\(^b\)\(^{c}\), Rongce Zhao\(^a\)\(^{b}\), Jingwen Zou\(^a\)\(^{b}\), Wenping Lin\(^a\)\(^{b}\), Jie Mei\(^a\)\(^{b}\), Wei Wei\(^a\)\(^{b}\) and Rongping Guo\(^a\)\(^{b}\)

\(^a\)Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China; \(^b\)State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; \(^c\)Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China

**ABSTRACT**

**Objective:** There is a lack of effective treatment to improve the prognosis of intrahepatic cholangiocarcinoma (ICC). Programmed cell death protein-1 (PD-1)-targeted immunotherapy has shown promising results in a variety of malignant tumours. However, in patients with advanced ICC, the safety and efficacy of anti-PD-1 agents remain unclear.

**Methods:** Forty-two advanced ICC patients treated with anti-PD-1 agents from August 2018 to December 2020 were retrospectively analyzed. Tumour response, overall survival (OS), progression-free survival (PFS), and time to tumour progression (TTP) were evaluated. Adverse events were also recorded.

**Results:** The median duration of follow-up was 12.1 months, and the median time of treatment was 6.7 months for all patients. The median OS, median PFS, and median TTP for the whole cohort were 19.3 months, 11.6 months, and 11.6 months, respectively. The overall response rate (ORR) and disease control rate (DCR) for the whole cohort were 23.8% and 85.7%, respectively. Of the 42 evaluable individuals, two (4.8%) had hyperprogressive disease. The most common adverse events (AEs) were pain (\(n = 6\); 14.3%), anorexia (\(n = 4\); 9.5%), hypertension (\(n = 4\); 9.5%), pyrexia (\(n = 3\); 7.1%), cough (\(n = 3\); 7.1%), and hypothyroidism (\(n = 3\); 7.1%). The median OS of patients with albumin-bilirubin (ALBI) grade 1 was longer than that of patients with ALBI grade 2 (19.3 months vs. 14.7 months). The median PFS did not show a significant difference between ALBI grade 1 and grade 2 patients (13.6 months vs. 6.9 months).

**Conclusions:** PD-1-targeted immunotherapy showed promising efficacy and safety in advanced ICC patients.

**KEY MESSAGES**

- PD-1-targeted immunotherapy is a safe and effective treatment for advanced ICC patients.
- This study provides therapeutic strategy for advanced ICC patients.

**Introduction**

Intrahepatic cholangiocarcinoma (ICC), one of the primary liver cancers, is the second most common liver malignancy after hepatocellular carcinoma (HCC) [1,2]. Owing to early local invasion, distant metastasis, and lack of effective treatment, the prognosis of ICC is still poor [3,4]. At present, only a small number of patients with ICC have the opportunity to undergo curative resection. However, even with radical resection, it is challenging for patients to achieve a median survival of more than 30 months [3]. Especially for patients with advanced ICC, few effective therapies can improve the clinical prognosis [5]. Consequently, more efficient treatments are urgently needed for ICC patients.

In recent years, immune checkpoint inhibitors (ICIs), specifically, programmed cell death protein-1 (PD-1)/programmed cell death protein ligand-1 (PD-L1) inhibitors, have achieved satisfactory results in treating some malignancies [6–8].
Research has shown that high PD-L1 expression can be detected in occupational cholangiocarcinoma (cholangiocarcinoma caused by occupational exposure to organic solvents), suggesting that the critical mechanism for forming occupational cholangiocarcinoma may be related to the immune escape of the PD-1/PD-L1 pathway [9]. Another ICC study reported that the upregulation of PD-1/PD-L1 expression in tumour tissues was relevant to tumour differentiation and American Joint Committee on Cancer (AJCC) staging [10]. In addition, a survey of 54 ICC patients showed that high expression of PD-L1 in tumours was associated with lower overall survival (OS) [11].

In current clinical practice, although ICIs have been widely used in HCC, PD-1/PD-L1 inhibitors are still rarely applied to ICC, and their efficacies in the real world are unknown. Noticeably, immunotherapy seems to have therapeutic prospects in biliary tract cancer, but more studies are needed to confirm it [12–16]. Therefore, we designed this study to evaluate the safety and efficacy of anti-PD-1 immune therapy in a real-world treatment cohort of advanced ICC patients in our cancer centre.

Patients and methods

Study design and patients

Our study is a single-centre retrospective analysis of advanced ICC patients who received anti-PD-1 agents at Sun Yat-sen University Cancer Centre (Guangzhou, China). Patients with radiologically or histologically confirmed advanced ICC who received PD-1 inhibitor monotherapy with nivolumab, pembrolizumab, toripalimab, camrelizumab, sintilimab, or tislelizumab or a combination therapy with other modes of cancer treatments were eligible. Histopathological diagnosis of ICC was based on the World Health Organization criteria [17]. The patient’s informed consent and confidentiality of information were obtained before the treatment. The retrospective analysis was approved by the Clinical Research Ethics Committee of Sun Yat-sen University Cancer Centre (No. B20203180). The Declaration of Helsinki on biomedical research involving human participants has also been followed.

Dosing of PD-1 inhibitor therapy

Nivolumab and toripalimab were intravenously administered at a fixed dose of 240 mg every 3 weeks. Pembrolizumab, camrelizumab, sintilimab, and tislelizumab were given at a fixed dose of 200 mg every 3 weeks intravenously.

Assessments

Patient information was collected before and after PD-1 inhibitor treatment. Clinicopathological data are shown in Table 1. In addition, tumours were evaluated by abdominal computed tomography (CT)/magnetic resonance imaging (MRI) at baseline. Tumour size, the

| Table 1. Baseline characteristics. |
|-----------------------------------|
| N = 42                           |
| Age (y), mean ± SD               | 55.5 ± 10.5 |
| Gender                           |
| Male                             | 28 (66.7%) |
| Female                           | 14 (33.3%) |
| Aetiology                        |
| Hepatitis B                      | 19 (45.2%) |
| Non-Hepatitis B                  | 23 (54.8%) |
| Child-Pugh stage                 |
| A                                | 42 (100%)  |
| B                                | 38 (90.5%) |
| C                                | 4 (9.5%)   |
| ECOG PS                          |
| 0                                | 5 (11.9%)  |
| 1                                | 35 (83.3%) |
| 2                                | 2 (4.8%)   |
| BCLC stage                       |
| A                                | 1 (2.4%)   |
| B                                | 4 (9.5%)   |
| C                                | 37 (88.1%) |
| Extrahepatic metastasis          |
| Lymp node metastasis             | 18 (42.9%) |
| Organ metastasis                 | 6 (14.3%)  |
| Lymp node metastasis and organ metastasis | 8 (19.0%) |
| Number of tumour                 |
| Single                           | 12 (28.6%) |
| Multiple                         | 30 (71.4%) |
| Tumour size (cm)                 | 7.6 ± 3.2  |
| AFP                              |
| <400 (ng/ml)                     | 32 (76.2%) |
| ≥400 (ng/ml)                     | 10 (23.8%) |
| PIVKA-II                         |
| ≤40 (mAU/mL)                     | 24 (57.1%) |
| >40 (mAU/mL)                     | 18 (42.9%) |
| CA19-9                           |
| ≤35 (U/ml)                       | 19 (45.2%) |
| >35 (U/ml)                       | 23 (54.8%) |
| Immunotherapy as systemic         |
| First-line                       | 35 (83.3%) |
| Second-line                      | 7 (16.7%)  |
| Prior treatment                  |
| Surgery                          | 7 (16.7%)  |
| TACE                             | 10 (23.8%) |
| HAIC                             | 22 (52.4%) |
| Radiation                        | 2 (4.8%)   |
| Chemotherapy                     | 4 (9.5%)   |
| Previous target therapy          | 7 (16.7%)  |
| Other treatments after PD-1 or combination |
| Surgery                          | 8 (19.0%)  |
| TACE                             | 10 (23.8%) |
| HAIC                             | 20 (47.6%) |
| Ablation                         | 1 (2.4%)   |
| Radiation                        | 4 (9.5%)   |
| Chemotherapy                     | 3 (7.1%)   |
| Sorafenib                        | 1 (2.4%)   |
| Lenvatinib                       | 20 (47.6%) |
| Apatinib                         | 15 (35.7%) |
| Regorafenib                      | 1 (2.4%)   |

ECOG PS: Eastern Cooperative Oncology Group Performance Status; BCLC: Barcelona-Clinic Liver Cancer; AFP: alpha-fetoprotein; PIVKA-II: protein induced by vitamin K absence or antagonist-II; CA19-9: Carbohydrate antigen 19-9; TACE: transcatheter arterial chemoembolization; HAIC: hepatic artery infusion chemotherapy.
number of nodules, vascular invasion, and tumour metastasis were assessed based on CT/MRI. Patients underwent CT or MRI examinations 4–8 weeks after the initiation of therapy and approximately every 2 months after evaluating the treatment efficacy. Hyperprogression was defined as a progressive disease in the first radiological assessment during immunotherapy (RECIST version 1.1 [18]) with a delta tumour growth rate of >50%, corresponding to an absolute increase in the tumour growth rate exceeding 50% per month.

The modified Response Evaluation Criteria in Solid Tumours (mRECIST [19]) was used to evaluate tumour response, including the following types: (I) complete response (CR); (II) partial response (PR); (III) stable disease (SD); and (IV) progressive disease (PD).

The endpoints, including overall survival (OS), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), and disease control rate (DCR), were examined in this study. OS was the time from the beginning of immunotherapy to death. Individuals who were still alive were censored at the date of the last follow-up or data cut-off. PFS was the time from first receiving PD-1 inhibitor to disease progression, confirmed by radiography, or death, whatever came first. Subjects who were still alive and without radiologically confirmed progression were censored at the date of last contact or data cut-off. TTP was the time from the date of first immunotherapy to initial confirmed tumour progression by imaging tests. Data from participants who died without radiologically confirmed tumour progression were censored at the last radiological evaluation date.

Albumin-bilirubin (ALBI) grade is a useful indicator for objective evaluation of liver function [20]. Studies have revealed that the ALBI grade can more accurately predict the patient’s prognosis and OS than the Child-Pugh grade [21,22]. The ALBI grade can be divided into 3 levels: grade 1, grade 2, and grade 3. The higher the score, the worse is the liver function [20,23]. The ALBI score was calculated from the formula ALBI score = (log10 bilirubin * 0.66) + (albumin – 0.085), where grade 1 is ≤ −2.60, grade 2 is −2.60 to −1.39, and grade 3 is > −1.39 [20].

Statistics

Descriptive statistics were used to analyze baseline characteristics, radiological tumour response, and adverse events. The comparison of nominal data used the chi-square test or Fisher’s exact test. Survival curves were calculated using the Kaplan–Meier method and compared utilizing the log-rank test. \( p < 0.05 \) was considered to be statistically significant. Comparisons among the six PD-1 drug groups were not conducted because the sample size was smaller after the cohort was subdivided. Statistical analyses were performed using IBM SPSS Statistics (version 26.0, SPSS Inc., Chicago, IL).

Results

Patients

This research included 42 ICC patients who received PD-1-targeted immunotherapy between August 2018 and December 2020. The data collection cut-off date was 31 December 31 2020. All 42 patients had at least one follow-up imaging assessment after receiving PD-1 immunotherapy to evaluate tumour response. Twenty-eight male and 14 female ICC patients with a median age of 55.5 years old (range from 29 to 75 years old) were enrolled.

At the beginning of PD-1 treatment, 42 ICC patients used different PD-1 antibodies as follows: nivolumab (\( n = 3 \)), pembrolizumab (\( n = 11 \)), sintilimab (\( n = 14 \)), toripalimab (\( n = 9 \)), camrelizumab (\( n = 4 \)), and tislelizumab (\( n = 1 \)). Immunotherapy was discontinued mainly due to radiological or clinical disease progression and adverse events. Immunotherapy was used as systemic first-line and second-line treatment in 35 (83.3%) and 7 (16.7%) patients, respectively. The patients’ main baseline features, including age, sex, aetiology, Child-Pugh stage, ECOG PS, BCLC stage, tumour characteristics, serum tumour marker level, and previous and subsequent treatments, are shown in Table 1. The median duration of follow-up was 12.1 (95%CI: 9.9–14.3) months for all patients. The median number of cycles of PD-1 therapy at the cut-off was 6.5 (95%CI: 6.2–9.9) for all patients. The median time of treatment was 6.7 (95%CI, 5.8–9.7) months for all patients. At the data cut-off, 9 (21.4%) patients were still receiving treatment with PD-1 immunotherapy.

Efficacy

Of the 42 patients, four (9.5%) participants achieved complete response (CR), and six (14.3%) patients achieved partial response (PR), resulting in an overall response rate (ORR) of 23.8%. Twenty-six (61.9%) patients showed stable disease (SD), and six (14.3%) patients had progressive disease (PD) at radiological evaluation. The disease control rate (DCR) was 85.7%. The results are shown in Table 2. None of the patients
were evaluated as having hyperprogression in this study.

Overall, 19 (45.2%) patients had radiological disease progression when receiving PD-1-targeted immunotherapy, and 12 (28.6%) participants died during follow-up. The median TTP was 11.6 (95% CI, 7.9–15.3) months for the whole cohort. The median OS was 19.3 (95% CI, 14.9–23.7) months for the whole cohort (Figure 1(A)). PFS was 11.6 (95% CI, 7.9–15.3) months for the entire group (Figure 1(B)), and TTP was equal to PFS. The median OS and median PFS for patients with non-PD were 19.3 (95% CI, 14.9–23.8) months and 13.6 (95% CI, 10.8–16.4) months, and the median OS and median PFS for patients with PD were 3.1 (95% CI, 1.2–4.0) months and 1.9 (95% CI, 0.1–3.7) months, respectively. The OS and PFS in patients with non-PD were significantly longer than those in patients with PD (Figure 2, All p < .001).

The median OS of PD-1 monotherapy (11.6 months, 95% CI, 8.6–14.6) was significantly shorter than that of PD-1 combined with other treatments (21.3 months, 95% CI, 14.7–27.9), such as transcatheter arterial chemoembolization (TACE) and hepatic artery infusion chemotherapy (HAIC) (p = .04). The median PFS was 10.6 (95% CI, 8.5–13.5) months and 11.5 (95% CI, 5.5–17.5) months for PD-1 monotherapy and PD-1 combined therapy, respectively (p = .59). The results are shown in Figure 3.

**Safety**

Twenty-one (50%) patients experienced at least one adverse event (AE). Grade ≥ 3 events occurred in two patients (4.8%), and grade 1 or grade 2 events occurred in 21 patients (50%). The most common adverse events were pain (n = 6; 14.3%), anorexia (n = 4; 9.5%), hypertension (n = 4; 9.5%), pyrexia (n = 3; 7.1%), cough (n = 3; 7.1%), and hypothyroidism (n = 3; 7.1%). Two (4.8%) patients developed adverse events of higher grade (grade ≥ 3), including pain (n = 1; 2.4%) and hepatitis (n = 1; 2.4%). PD-1 immunotherapy was discontinued, and corticosteroids were used in one patient with hepatitis. The remaining adverse events were treated symptomatically (n = 19; 45.2%). All adverse events observed in PD-1-treated patients are shown in Table 3. No patient died due to PD-1 immunotherapy during treatment. A dose delay due to adverse events was required in eight (19%) participants receiving PD-1 immunotherapy; of these patients, three (7.1%) were treated with pembrolizumab, three (7.1%) with sintilimab, one (2.4%) with nivolumab, and one (2.4%) with camrelizumab.

**Efficacy and safety according to ALBI grade**

The efficacy and safety of immunotherapy in patients with ALBI grades 1 and 2 were assessed. The ORR and DCR for ALBI grade 1 vs grade 2 were 19% vs 4.8% and 66.7% vs 19.0%, respectively. The median OS in patients with ALBI grade 1 (19.3 months, 95% CI, 14.9–23.8) was significantly longer than that of patients with ALBI grade 2 (14.7 months, 95% CI, 8.3–21.1) (p = .036). However, the median PFS in patients with ALBI grade 1 (13.6 months, 95% CI, 10.2–17.0) was not significantly different from that in patients with ALBI grade 2 (6.9 months, 95% CI, 4.1–9.7) (p = .13). The results are shown in Figure 4.

**Discussion**

Our single-centre retrospective study proved that PD-1-targeted immunotherapy exhibited promising efficacy and slight toxicity in a real-world cohort of patients with advanced ICC. The median OS and median PFS of

---

**Table 2. Tumour responses and survival.**

| Tumour response | All patients (n = 42) | Nivolumab | Pembrolizumab | Toripalimab | Camrelizumab | Sintilimab | Tislelizumab |
|-----------------|----------------------|-----------|---------------|-------------|--------------|------------|-------------|
| Tumour response | CR                   | 4 (9.5%)  | 0             | 0           | 1 (11.1%)    | 0          | 3 (21.4%)   |
|                 | PR                   | 6 (14.3%) | 0             | 1 (9.1%)    | 2 (22.2%)    | 0          | 1 (7.1%)    |
|                 | SD                   | 26 (61.9%)| 3 (100%)      | 9 (81.8%)   | 6 (66.7%)    | 1 (25%)    | 7 (50%)     |
|                 | PD                   | 6 (14.3%) | 0             | 1 (9.1%)    | 0            | 1 (25%)    | 3 (21.4%)   |
|                 | ORR (CR + PR)        | 10 (23.8%)| 0             | 1 (9.1%)    | 3 (33.3%)    | 2 (50%)    | 4 (28.6%)   |
|                 | DCR (CR + PR + SD)   | 36 (85.7%)| 3 (100%)      | 10 (90.9)   | 9 (100%)     | 3 (75%)    | 11 (78.6%)  |
| PFS, median (95% CI) | 11.6 (95% CI, 7.9–15.3) |
| TTP, median (95% CI) | 11.6 (95% CI, 7.9–15.3) |
| OS, median (95% CI)  | 19.3 (95% CI, 14.9–23.7) |
| 6 months survival rate | 90.5% |
| 1-year survival rate | 77% |
| 18 months survival rate | 57% |
| 2-year survival rate | 19% |

CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; ORR: overall response rate; DCR: disease control rate; PFS: progression-free survival; TTP: time to progression; OS: overall survival.
the patients with ORR in this research were significantly longer than those of the PD group (19.3 months vs. 3.1 months, 13.6 months vs. 1.9 months). There are few studies on PD-1 in the treatment of ICC patients in China. Moreover, the background of ICC disease in China is different from that in other countries. ICC patients in China often have bile duct stones, cholangitis, or HBV infection, while ICC patients in western countries, South Korea and Japan often have primary sclerosing cholangitis as the disease background [2,24–26]. The therapeutic efficacy of PD-1 in ICC patients in different countries may be diverse, and there is still no definite evidence. Therefore, our study may provide some evidence for the treatment of PD-1 in ICC with bile duct stones, cholangitis, and HBV background. In addition, the predictive effect of ALBI grade on PD-1 treatment in ICC patients was also analyzed. This study also evaluated the different efficacy between PD-1 combined with other therapies and PD-1 monotherapy in the treatment of ICC. ALBI grade is an index that can objectively evaluate liver function and accurately predict the prognosis of patients with
liver disease. ALBI grade plays a potential role in predicting prognosis in patients with advanced HCC receiving immunotherapy [27,28]. At present, there are no effective clinical indicators that can predict the efficacy of immunotherapy in ICC patients. ICC and HCC are both types of primary liver cancer. Tumour development and antitumor treatments may affect liver function. Accordingly, this study aims to use ALBI grade to predict the efficacy of immunotherapy and the prognosis of ICC patients. For the comparison between patients with different ALBI scores, the median OS of patients with ALBI grade 1 was longer than that of patients with ALBI grade 2 (19.3 months vs. 14.7 months). The median PFS did not show a significant difference between ALBI grade 1 and grade 2 patients, but the PFS of patients with ALBI grade 1 tended to be longer than that of patients with ALBI grade 2 (13.6 months vs. 6.9 months). Most of the adverse events relevant to PD-1 in this study were manageable, and only two patients developed severe adverse events.

Current studies show that ICIs combined with other medications may improve the therapeutic efficacy towards malignant tumours [29–31]. Encouragingly, ICI monotherapy or combination therapy has shown particular curative efficacy in the most common liver cancer, HCC [32–34]. In this study, the median OS of patients with PD-1 combined therapy was longer than that of patients with PD-1 monotherapy (21.3 months vs. 11.6 months). Regrettably, the median PFS between the two groups was not significantly different (11.5 months vs. 10.6 months), which may be due to the small sample size. However, from the perspective of the trend, the combined treatment has a better efficacy. Owing to the small sample size of patients with ICC, our study did not compare the efficacy of various combination therapies or analyze when the combined treatment with a PD-1 agent is the best. Current studies have shown that the efficacy of combining other therapies at the beginning of PD-1 treatment is better. The original treatment plan should be replaced when the disease progresses after the combined treatment. From the above studies, it can be seen that ICIs have achieved breakthrough results in the treatment of advanced HCC; nevertheless, the ORR and OS of single-agent therapy need to be improved. Combination therapy may be the inevitable direction of ICIs in the treatment of advanced HCC.

Biliary tract cancers (BTCs) include intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder carcinoma [35]. Existing studies have shown that the prognosis of these types of cholangiocarcinomas and the effectiveness of treatments are different, especially for systematic treatment [36,37]. Cisplatin combined with gemcitabine is considered

Table 3. Adverse events.

| Effect                  | All patients (n = 42) |
|-------------------------|----------------------|
|                         | Any grade | Grade ≥ 3 |
| Pyrexia                 | 3 (7.1%) | – |
| Rash                    | 1 (2.4%) | – |
| Fatigue                 | 1 (2.4%) | – |
| Anorexia                | 4 (9.5%) | – |
| Palpitation             | 1 (2.4%) | – |
| Hiccups                 | 1 (2.4%) | – |
| Nausea                  | 2 (4.8%) | – |
| Vomiting                | 2 (4.8%) | – |
| Pain                    | 6 (14.3%) | 1 (2.4%) |
| Headache                | 1 (2.4%) | – |
| Low back pain           | 1 (2.4%) | – |
| Cough                   | 3 (7.1%) | – |
| Diarrhoea               | 2 (4.8%) | – |
| Abdominal distension    | 1 (2.4%) | – |
| Arthralgia              | 1 (2.4%) | – |
| Dental ulcer            | 2 (4.8%) | – |
| Hypothyroidism          | 3 (7.1%) | – |
| Hypertension            | 4 (9.5%) | – |
| Constipation            | 2 (4.8%) | – |
| Hypoproteinemia         | 1 (2.4%) | – |
| Myelosuppression        | 2 (4.8%) | – |
| Immune associated pneumonia | 1 (2.4%) | – |
| Hand-foot skin reaction | 1 (2.4%) | – |
| Hepatitis               | 2 (4.8%) | 1 (2.4%) |
| Peripheral neuropathy   | 1 (2.4%) | – |

Figure 4. Kaplan–Meier curves showing OS and PFS for patients with different ALBI grades. (A) OS rates in patients with ALBI grade 1 and grade 2. (B) PFS rates in patients with ALBI grade 1 and grade 2.
the standard first-line chemotherapy for advanced BTC [38]. However, in patients with ICC, the efficacy is unsatisfactory [39,40]. ICC, a type of primary liver cancer, can be treated in a similar manner as HCC [3]. Some studies have shown that TACE in locally advanced ICC can achieve curative effects similar to those of palliative surgical resection [41]. Postoperative adjuvant TACE, radiotherapy and other local treatments can significantly reduce tumour recurrence and improve survival [42,43]. For ICC patients with a hepatitis B virus infection background, postoperative antiviral therapy can significantly reduce tumour recurrence [44]. These findings are similar to those of many HCC treatments.

Compared with HCC, an effective treatment for ICC is even more lacking [2,3]. However, targeted PD-1 therapy has been approved for advanced ICC with microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR). The efficacy of immune checkpoint therapy in mismatch repair proficient (pMMR) and microsatellite stable (MSS) ICC is still unclear, and the predictive effect of tumour mutation burden (TMB) and PD-L1 expression status is also inconclusive [45–47]. Furthermore, a new generation of bifunctional checkpoint inhibitors, M7824, can simultaneously target PD-L1 and TGF-β and further improve the effectiveness of immunotherapy by effectively inhibiting immune escape. A phase III clinical trial of M7824 combined with chemotherapy as a first-line treatment for advanced cholangiocarcinoma is in progress [48]. In the future, systemic treatment of ICC, including immunotherapy, can learn from the experience of HCC therapies. In the next few years, multicenter randomized-controlled studies on ICC immunotherapy will be an important trend in clinical research of advanced ICC. The combination of ICIs with chemotherapy, targeted therapy, and local treatment will be also a hot spot worthy of attention.

We admit that there are some shortcomings in this research. First, our study is a retrospective analysis, which has inevitable bias. Second, the sample size of this study was small, and the conclusions of the research were not strong enough. For example, the efficacy of several PD-1 inhibitors cannot be compared. Similarly, the best treatment cannot be distinguished among various combination treatments. Third, the ICC patients in our cancer centre had not undergone genetic testing. Since it is a trend to combine molecular markers to predict efficacy, molecular markers may better indicate the efficacy of immune or targeted therapy and suggest more suitable combination therapies. For example, the bifunctional checkpoint inhibitor M7824 can significantly benefit cholangiocarcinoma patients with positive expression of PD-L1 and TGF-β. Therefore, anti-PD-1 agents combined with molecular targeted inhibitors may achieve better efficacy in PD-1 positive patients.

In conclusion, PD-1-targeted immunotherapy is a safe and effective treatment for advanced ICC patients and provides another therapeutic strategy for these patients.

Acknowledgements

The authors acknowledge and express their deepest gratitude to the participants of this research.

Ethics approval

The study was a retrospective review of medical records. The study protocol was approved by the Clinical Research Ethics Committee of SYSUCC.

Disclosure statement

None of the authors does not have any conflicts of interests.

This study was supported by the National Natural Science Foundation of China [No. 82172579, No. 81871985]; Natural Science Foundation of Guangdong Province [No. 2018A0303130098]; Science and Technology Planning Project of Guangdong Province [No. 2017A020215112]; Science and Technology Planning Project of Guangzhou [No. 201903010017 and No. 201904010479]; Clinical Trials Project [5010 Project] of Sun Yat-sen University [No. 5010-2017009]; Clinical Trials Project [308 Project] of Sun Yat-sen University Cancer Centre [No. 308-2015-014]; and Medical Innovation Project of the First Affiliated Hospital of Guangzhou University of Chinese Medicine [2019IIIT18].

Data availability statement

The data that support the findings of this study are available from the corresponding author.

Informed consent statement

Our study is a retrospective study. Consent was obtained before the patient received PD-1 targeted immunotherapy. The obtained consent was initially used for other studies, but the consent specifically mentioned the patient’s clinical data might be used for other subsequent clinical studies, such as retrospective studies. The study protocol was approved by the Clinical Research Ethics Committee of SYSUCC, and all patients provided written informed consent before receiving PD-1 targeted immunotherapy (No. B20203180).
Refereces

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.

[2] Valle JW, Kelley RK, Nervi B, et al. Biliary tract cancer. Lancet. 2021;397(10272):428–444.

[3] Sirica AE, Gores GJ, Groopman JD, et al. Intrahepatic cholangiocarcinoma: continuing challenges and translational advances. Hepatology. 2019;69(4):1803–1815.

[4] Patel T. Cholangiocarcinoma—controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011;8(4):189–200.

[5] Mavros MN, Economopoulos KP, Alexiou VG, et al. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. N Engl J Med. 2015;372(20):2509–2520.

[6] Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(20):2509–2520.

[7] Kansy BA, Concha-Benavente F, Srivastava RM, et al. PD-1 status in CD8+ T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer. Cancer Res. 2017;77(22):6353–6364.

[8] Migden MR, Rischin D, Schmuits CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341–351.

[9] Sato Y, Kinoshita M, Takemura S, et al. The PD-1/PD-L1 axis may be aberrantly activated in occupational cholangiocarcinoma. Pathol Int. 2017;67(3):163–170.

[10] Ye Y, Zhou L, Xie X, et al. Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion. J Surg Oncol. 2009;100(6):500–504.

[11] Gani F, Nagarajan N, Kim Y, et al. Program death 1 immune checkpoint and tumor microenvironment: Implications for patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2016;23(8):2610–2617.

[12] Ricci AD, Rizzo A, Brandi G. Immunotherapy in biliary tract cancer: worthy of a second look. Cancer Control. 2020;27(3):1073274820948047.

[13] Boilève A, Hilmi M, Smolenschi C, et al. Immunotherapy in advanced biliary tract cancers. Cancers (Basel). 2021;13(7):1569.

[14] Rizzo A, Ricci AD, Brandi G. Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol. 2021;15(5):527–536.

[15] Guo X, Shen W. Latest evidence on immunotherapy for cholangiocarcinoma. Oncol Lett. 2020;20(6):381.

[16] Rizzo A, Ricci AD, Brandi G. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opin Investig Drugs. 2021;30(4):343–350.

[17] Nagtegaal ID, WHO Classification of Tumours Editorial Board, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–188.

[18] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.

[19] Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.

[20] Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. J Clin Oncol. 2015;33(6):550–558.

[21] Chan A, Leung H, Chong C, et al. Validating the ALBI grade: Its current and future use in HCC prognostication. J Hepatol. 2017;66(3):661–663.

[22] Pinato DJ, Sharma R, Allara E, et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol. 2017;66(2):338–346.

[23] Deng M, Ng S, Cheung ST, et al. Clinical application of Albumin-Bilirubin (ALBI) score: the current status. Surgeon. 2020;18(3):178–186.

[24] Brandley PJ, Bachini M, Ilyas SI, et al. Cholangiocarcinoma. Nat Rev Dis Primers. 2021;7(1):65.

[25] Lee SH, Lee HS, Lee SH, et al. Efficacy and safety of pembrolizumab for gemcitabine/Cisplatin-Refractory biliary tract cancer: a multicenter retrospective study. J Clin Med. 2020;9(6):1769.

[26] Kang J, Jeong JH, Hwang HS, et al. Efficacy and safety of pembrolizumab in patients with refractory advanced biliary tract cancer: tumor proportion score as a potential biomarker for response. Cancer Res Treat. 2020;52(2):594–603.

[27] Pinato DJ, Kaneko T, Saeed A, et al. Immunotherapy in hepatocellular cancer patients with mild to severe liver dysfunction: adjunctive role of the ALBI grade. Cancers (Basel). 2020;12(7):1862.

[28] Wong J, Kwok G, Tang V, et al. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. J Immunother. 2021;44(2):e001945.

[29] Hilmi M, Neuzillet C, Calderaro J, et al. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. J Immunother Cancer. 2019;7(1):333.

[30] D’Andrea MA, Reddy GK. Systemic immunostimulatory effects of radiation therapy improves the outcomes of patients with advanced NSCLC receiving immunotherapy. Am J Clin Oncol. 2020;43(3):218–228.

[31] Bang YJ, Golan T, Dahan L, et al. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: an open-label, phase Ia/b study (JVDJ). Eur J Cancer. 2020;157:272–284.

[32] Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–952.

[33] Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevazucizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905.
[34] Lai E, Astara G, Ziranu P, et al. Introducing immuno-
therapy for advanced hepatocellular carcinoma
patients: too early or too fast. Crit Rev Oncol
Hematol. 2021;157:103167.

[35] Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet.
2014;383(9935):2168–2179.

[36] Banales JM, Marin J, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mecha-
nisms and management. Nat Rev Gastroenterol
Hepatol. 2020;17(9):557–588.

[37] Massironi S, Pilla L, Elvevi A, et al. New and emerging
systemic therapeutic options for advanced cholangi-
ocarcinoma. Cells. 2020;9(3):688.

[38] Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gem-
citabine versus gemcitabine for biliary tract cancer. N
Engl J Med. 2010;362(14):1273–1281.

[39] Ebata T, Bile Duct Cancer Adjuvant Trial (BCAT) Study
Group, Hirano S, Konishi M, et al. Randomized clinical
trial of adjuvant gemcitabine chemotherapy versus
observation in resected bile duct cancer. Br J Surg.
2018;105(3):192–202.

[40] Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveil-
ance in resected biliary tract cancer (PRODIGE 12-
ACCORD 18-UNICANCER GI): a randomized phase III
study. J Clin Oncol. 2019;37(8):658–667.

[41] Scheuermann U, Kathal JM, Heise M, et al. Comparison
of resection and transarterial chemoembolisation in
the treatment of advanced intrahepatic cholangiocar-
cinoma—a single-center experience. Eur J Surg Oncol.
2013;39(6):593–600.

[42] Li J, Wang Q, Lei Z, et al. Adjuvant transarterial chemo-
embolization following liver resection for intrahepa-
tic cholangiocarcinoma based on survival risk
stratification. Oncologist. 2015;20(6):640–647.

[43] Hammad AY, Berger NG, Eastwood D, et al. Is radio-
therapy warranted following intrahepatic cholangio-
carcinoma resection? The impact of surgical margins
and lymph node status on survival. Ann Surg Oncol.
2016;23(S5):912–920.

[44] Sha M, Jeong S, Xia Q. Antiviral therapy improves sur-
vival in patients with HBV infection and intrahepatic
cholangiocarcinoma undergoing liver resection: novel
concerns. J Hepatol. 2018;68(6):1315–1316.

[45] Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone
or in combination with cisplatin plus gemcitabine in
Japanese patients with unresectable or recurrent bili-
ary tract cancer: a non-randomised, multicentre,
open-label, phase 1 study. Lancet Gastroenterol
Hepatol. 2019;4(8):611–621.

[46] Piha-Paul SA, Oh DY, Ueno M, et al. Efficacy and
safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-
158 and KEYNOTE-028 studies. Int J Cancer. 2020;
147(8):2190–2198.

[47] Kim RD, Chung V, Alese OB, et al. A phase 2 multi-
institutional study of nivolumab for patients with
advanced refractory biliary tract cancer. JAMA Oncol.
2020;6(6):888–894.

[48] Yoo C, Oh DY, Choi HJ, et al. Phase I study of bintra-
fusp alfa, a bifunctional fusion protein targeting TGF-
β and PD-L1, in patients with pretreated biliary tract
cancer. J Immunother Cancer. 2020;8(1):e000564.